Oral N-acetylcysteine for Retinitis Pigmentosa
Oral N-acetylcysteine for Retinitis Pigmentosa
Active, not recruiting · NCT05537220 · Registry updated 2026-06-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Oral N-acetylcysteine for Retinitis Pigmentosa | Abnormalities, Multiple, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Deaf-Blind Disorders, Deafness, Ear Diseases, Eye Diseases, Hereditary, Hearing Loss, Sensorineural, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, Usher syndrome, blindness (disorder), eye disorder, hearing disorder, hearing loss disorder, hereditary disease, inherited retinal dystrophy, nervous system disorder, otorhinolaryngologic disease, retinal degeneration, retinal disorder, retinitis pigmentosa, vision disorder | Active, not recruiting | Phase 3 | 2026-06-15 | NCT05537220 |
32 results · Page 1 of 2
Organizations
Swipe the table sideways for more columns.
31 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.